Suven Life Sciences
Ticker > Company >

Suven Life Sciences share price

Suven Life Sciences Ltd.

NSE: SUVEN BSE: 530239 SECTOR: Pharmaceuticals & Drugs  1.03 L   148   27

201.75
-7.60 (-3.63%)
BSE: 29 Sep 04:01 PM

Price Summary

Today's High

₹ 206.1

Today's Low

₹ 200

52 Week High

₹ 303

52 Week Low

₹ 102.7

FinStar

Ownership Stable
Ownership strength is slightly missing the benchmark.
ValuationFair
The stock’s market price justifies its intrinsic value.
EfficiencyPoor
The company seems highly inefficient in case of asset management.
FinancialsWeak
Watch out! The company might not be able to sustain any adverse condition.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

₹ 4589.29 Cr.

Enterprise Value

₹ 4569.33 Cr.

No. of Shares

22.75 Cr.

P/E

0

P/B

5.06

Face Value

₹ 1

Div. Yield

0 %

Book Value (TTM)

₹  39.85

CASH

₹ 19.96 Cr.

DEBT

₹ 0 Cr.

Promoter Holding

70.27 %

EPS (TTM)

₹  -2.38

Sales Growth

-43.08%

ROE

-5.73 %

ROCE

-5.71%

Profit Growth

-487.89 %

Add Your Ratio

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.

PE Chart 1w 1m 3m 6m 1Yr 3Yr 5Yr

PB Chart 1w 1m 3m 6m 1Yr 3Yr 5Yr

* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year-43.08%
3 Year-17.48%
5 Year-14.32%

Profit Growth

1 Year-487.89%
3 Year-11.16%
5 Year-207.31%

ROE%

1 Year-5.73%
3 Year-3.23%
5 Year-4.87%

ROCE %

1 Year-5.71%
3 Year-3.24%
5 Year-4.93%

Debt/Equity

0

Price to Cash Flow

-96.84

Interest Cover Ratio

-317.7529

CFO/PAT (5 Yr. Avg.)

0

Shareholding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Jun 2025 70.27 0.00
Mar 2025 70.27 0.00
Dec 2024 70.27 0.00
Sep 2024 70.27 0.00
Jun 2024 70.27 0.00
Investors List
* Figures given above are % of equity capital

 Strengths

  • Company is virtually debt free.
  • Company has a healthy liquidity position with current ratio of 7.5235.
  • The company has a high promoter holding of 70.27%.
  • The company has a strong degree of Operating leverage, Average Operating leverage stands at 3.04741352902646.

 Limitations

  • The company has shown a poor profit growth of -11.1590292731075% for the Past 3 years.
  • The company has shown a poor revenue growth of -17.4790050028496% for the Past 3 years.
  • Company has a poor ROE of -3.2332% over the past 3 years.
  • Company has a poor ROCE of -3.23543333333333% over the past 3 years
  • Company has negative cash flow from operations of -47.3907.
  • The company has a low EBITDA margin of -356.230590401906% over the past 5 years.

Quarterly Result (All Figures in Cr.)

PARTICULARS Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025
Net Sales 1.01 2.57 1.61 1.47 1.87
Total Expenditure 11.09 16.21 14.91 16.38 15.87
Operating Profit -10.09 -13.64 -13.3 -14.91 -14
Other Income 3.93 4.04 1.57 1.19 0.59
Interest 0.02 0.02 0.01 0 0
Depreciation 1.49 1.46 1.53 1.35 1.37
Exceptional Items 0 0 0 0 0
Profit Before Tax -7.67 -11.07 -13.27 -15.07 -14.78
Tax 0 0 0 0 0
Profit After Tax -7.67 -11.07 -13.27 -15.07 -14.78
Adjusted EPS (Rs) -0.35 -0.51 -0.61 -0.69 -0.68

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Net Sales 13.48 11.84 13.54 11.69 6.66
Total Expenditure 43.93 48.37 41.18 42.55 58.49
Operating Profit -30.45 -36.53 -27.64 -30.85 -51.84
Other Income 7.75 1.6 8.45 21.13 10.73
Interest 0.91 0.64 0.4 0.24 0.15
Depreciation 4.35 4.39 6.54 6.5 5.82
Exceptional Items 0 3.72 6 7.46 0
Profit Before Tax -27.95 -36.25 -20.13 -9.01 -47.08
Tax -5.32 0 0 -1 0
Net Profit -22.63 -36.25 -20.13 -8.01 -47.08
Adjusted EPS (Rs.) -1.64 -2.3 -0.92 -0.37 -2.16

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Equity and Liabilities
Share Capital 12.73 14.54 21.81 21.81 21.81
Total Reserves 388.93 461.44 831.64 823.57 777.7
Borrowings 0.39 0 0 0 0
Other N/C liabilities 4.11 3.57 2.46 1.35 1.71
Current liabilities 103.13 100.7 98.43 4.76 7.67
Total Liabilities 509.28 580.25 954.34 851.48 808.89
Assets
Net Block 20.96 37.56 37.21 28.21 59.65
Capital WIP 4.77 3.55 0 0 0.01
Intangible WIP 0 0 0 0 0
Investments 295.03 380.69 481.86 577.11 691.47
Loans & Advances 0 0.33 0.11 0.02 0.05
Other N/C Assets 0 0 100 0 0
Current Assets 188.52 158.12 335.16 246.14 57.71
Total Assets 509.28 580.25 954.34 851.48 808.89
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Profit from operations -27.96 -36.25 -20.13 -9.01 -47.08
Adjustment -2.7 -1.09 -8.09 -22.46 -3.92
Changes in Assets & Liabilities -4.88 1.24 6.4 4.73 3
Tax Paid -1.15 -0.52 -1.1 6.18 0.61
Operating Cash Flow -36.68 -36.62 -22.92 -20.56 -47.39
Investing Cash Flow 2.41 -107.46 -348.82 -0.68 44.21
Financing Cash Flow 34.86 145.69 395.54 -1.05 -0.76
Net Cash Flow 0.58 1.61 23.79 -22.3 -3.94

Corporate Actions

Investors Details

PARTICULARS Jun 2024% Sep 2024% Dec 2024% Mar 2025% Jun 2025%
promoters 70.27 70.27 70.27 70.27 70.27
jasti property and equity... - - - - 69.56
sudharani jasti 0.70 0.70 0.70 0.70 0.70
jasti property and equity... 69.56 69.56 69.56 69.56 -
PARTICULARS Jun 2024% Sep 2024% Dec 2024% Mar 2025% Jun 2025%
investors 29.73 29.73 29.73 29.73 29.73
investor education and pr... - 0.12 - - 0.14
investor education and pr... 0.12 - 0.12 0.14 -
quant mutual fund - quant... 1.05 1.05 1.05 - -
rambabu chirumamilla 1.38 1.38 1.38 - -

Annual Reports

Title Link
Title Link
Annual Report 2025
Annual Report 2023
Annual Report 2022
Annual Report 2021
Annual Report 2020
Annual Report 2019
Annual Report 2018
Annual Report 2017

Ratings & Research Reports

TYPE AGENCY Link
TYPE AGENCY Link
Credit CRISIL
Credit CRISIL
Credit CRISIL
Credit CRISIL
Credit CARE
TYPE AGENCY Link
TYPE AGENCY Link
Research Geojit BNP Paribas

Concalls & Presentations

TYPE QUARTER Link
TYPE QUARTER Link
 Currently we do not have any Concall related to this company.Report us
TYPE QUARTER Link
TYPE QUARTER Link
Presentation Q2FY19

Company News

Suven Life Sciences - Quaterly Results 13 Aug, 12:52 PM Suven Life Sciences - Quaterly Results 13 Aug, 12:52 PM Suven Life Sciences - Quaterly Results 13 Aug, 12:52 PM Suven Life Sciences informs about outcome of board meeting 3 Jul, 5:34 PM Suven Life Sciences informs about disclosure 5 Jun, 5:29 PM Suven Life Sciences informs about outcome of board meeting 13 May, 5:03 PM Suven Life Sciences - Quaterly Results 13 May, 12:37 PM Suven Life Sciences - Quaterly Results 13 May, 12:37 PM Suven Life Sciences - Quaterly Results 13 May, 12:37 PM Suven Pharmaceuticals informs about disclosure 12 May, 10:42 AM Suven Life Sciences informs about certificate 2 Apr, 11:47 AM Suven Life Sciences - Quaterly Results 24 Jan, 4:18 PM Suven Life Sciences - Quaterly Results 24 Jan, 4:18 PM Suven Life Sciences - Quaterly Results 24 Jan, 4:18 PM Suven Life Sciences informs about certificate 8 Jan, 2:40 PM Suven Life Sciences informs about newspaper publication 3 Dec, 4:24 PM Suven Life Sciences - Quaterly Results 29 Oct, 12:51 PM Suven Life Sciences - Quaterly Results 29 Oct, 12:51 PM Suven Life Sciences - Quaterly Results 29 Oct, 12:51 PM Suven Life Sciences informs about certificate 7 Oct, 5:19 PM Suven Life Sciences informs about newspaper advertisement 6 Aug, 5:15 PM Suven Life Sciences - Quaterly Results 5 Aug, 1:12 PM Suven Life Sciences - Quaterly Results 5 Aug, 1:12 PM Suven Life Sciences - Quaterly Results 5 Aug, 1:12 PM Suven Pharmaceuticals informs about appointment of statutory auditors 13 Jul, 11:09 AM Suven Life Sciences informs about AGM notice 4 Jul, 5:22 PM Suven Life Sciences - Quaterly Results 6 May, 6:45 PM Suven Life Sciences - Quaterly Results 6 May, 6:45 PM Suven Pharmaceuticals to merge Cohance with itself 1 Mar, 11:30 AM Suven Life Sciences - Quaterly Results 30 Jan, 12:57 PM Suven Life Sciences - Quaterly Results 30 Jan, 12:57 PM Suven Life Sciences - Quaterly Results 30 Jan, 12:57 PM Suven Pharmaceuticals informs about board meeting 29 Jan, 5:23 PM Suven Pharmaceuticals informs about BRSR 23 Nov, 4:15 PM Suven Life Sciences - Quaterly Results 4 Nov, 12:41 PM Suven Life Sciences - Quaterly Results 4 Nov, 12:41 PM Suven Life Sciences - Quaterly Results 4 Nov, 12:41 PM Suven Pharmaceuticals informs about disclosure 26 Sep, 5:07 PM Suven Life Sciences informs about loss of share certificate 16 Sep, 3:58 PM CCEA approves foreign investment of up to Rs 9589 crore in Suven Pharmaceuticals 14 Sep, 4:37 PM Suven Life Sciences informs about monitoring agency report 9 Aug, 4:34 PM Suven Life Sciences - Quaterly Results 8 Aug, 1:02 PM Suven Life Sciences - Quaterly Results 8 Aug, 1:02 PM Suven Life Sciences - Quaterly Results 8 Aug, 1:02 PM Suven Life Sciences informs about newspaper publication 10 May, 1:09 PM Suven Life Sciences - Quaterly Results 9 May, 1:14 PM Suven Life Sciences - Quaterly Results 9 May, 1:14 PM Suven Life Sciences - Quaterly Results 9 May, 1:14 PM Suven Life Sciences informs about loss of share certificate 6 Mar, 5:00 PM Suven Life Sciences informs about monitoring agency report 9 Feb, 4:55 PM

Suven Life Sciences Stock Price Analysis and Quick Research Report. Is Suven Life Sciences an attractive stock to invest in?

Stock investing requires careful analysis of financial data to determine a company's true net worth. This is generally done by examining the company's profit and loss account, balance sheet and cash flow statement, which can be time-consuming and cumbersome.

Examining a company's financial ratios is an easier way to determine its performance, which can help to make sense of the overwhelming amount of information in its financial statements. 

Here are a few indispensable ratios that should be a part of every investor’s research process, or, in simpler words, how to analyse Suven Life Sciences. 

  • PE ratio: Price to Earnings ratio, which indicates how much an investor is willing to pay for a share for every rupee of earnings. A general rule of thumb is that shares trading at a low P/E are undervalued (it depends on other factors too). Suven Life Sciences has a PE ratio of -84.6877098723976 which is low and comparatively undervalued.

  • Return on Assets (ROA): Return on Assets measures how effectively a company can earn a return on its investment in assets. In other words, ROA shows how efficiently a company can convert the money used to purchase assets into net income or profits. Suven Life Sciences has ROA of -5.671% which is a bad sign for future performance. (Higher values are always desirable.)

  • Current ratio: The current ratio measures a company's ability to pay its short-term liabilities with its short-term assets. A higher current ratio is desirable so that the company could be stable to unexpected bumps in business and economy. Suven Life Sciences has a Current ratio of 7.5235.

  • Return on equity: ROE measures the ability of a firm to generate profits from its shareholders' investments in the company. In other words, the return on equity ratio shows how much profit each rupee of common stockholders’ equity generates. Suven Life Sciences has a ROE of -5.7288%. (Higher is better)

  • Debt to equity ratio: It is a good metric to check out the capital structure along with its performance. Suven Life Sciences has a Debt to Equity ratio of 0 which means that the company has low proportion of debt in its capital.

  • Sales growth: Suven Life Sciences has reported revenue growth of -43.0788% which is poor in relation to its growth and performance. 

  • Operating Margin: This will tell you about the operational efficiency of the company. The operating margin of Suven Life Sciences for the current financial year is -778.813966765828%.

  • Dividend Yield: It tells us how much dividend we will receive in relation to the price of the stock. The current year dividend for Suven Life Sciences is Rs 0 and the yield is 0%.

  • Earnings Per Share: It tells us how much profit is allocated to to each outstanding share of a common stock. The latest EPS of Suven Life Sciences is Rs -2.3824. The higher the EPS, the better it is for investors. 

One can find all the Financial Ratios of Suven Life Sciences in Ticker for free. Also, one can get the intrinsic value of Suven Life Sciences by using Valuation Calculators, which are available with a Finology ONE subscription. 

Suven Life Sciences FAQs

Q1. What is Suven Life Sciences share price today?
Ans: The current share price of Suven Life Sciences is Rs 201.76.

Q2. What is the market capitalisation of Suven Life Sciences?
Ans: Suven Life Sciences has a market capitalisation of Rs 4589.519600432 Cr., calculated based on its latest share price.

Q3. What are the P/E and P/B ratios of Suven Life Sciences?
Ans: The PE ratio of Suven Life Sciences is -84.6877098723976 and the P/B ratio of Suven Life Sciences is 5.06246534233617, showing how the stock is valued against its earnings and book value.

Q4. What is the 52-week high and low of Suven Life Sciences share?
Ans: The 52-week high share price of Suven Life Sciences is Rs 299.99, and the 52-week low share price of Suven Life Sciences is Rs 102.5.

Q5. Does Suven Life Sciences pay dividends?
Ans: Currently, Suven Life Sciences does not pay dividends. Dividend yield of Suven Life Sciences is around 0%.

Q6. What are the face value and book value of Suven Life Sciences shares?
Ans: The face value of Suven Life Sciences shares is Rs 1, while the book value per share of Suven Life Sciences is around Rs 39.8541. Face value is the nominal value set by the company, whereas book value reflects its accounting worth.

Q7. What is the debt of Suven Life Sciences?
Ans: Suven Life Sciences has a total debt of Rs 0 Cr., which affects investor sentiment and financial stability. 

Q8. What are the ROE and ROCE of Suven Life Sciences?
Ans: The ROE of Suven Life Sciences is -5.7288% and ROCE of Suven Life Sciences is -5.7064%. ROE shows how efficiently the company is generating profit from shareholders’ equity, while the ROCE is reflects how efficiently the company uses its capital to generate returns.

Q9. Is Suven Life Sciences a good buy for the long term?
Ans: The Suven Life Sciences long-term outlook depends on debt levels, earnings growth, and sector trends. If it sustains profits and manages debt well, it may be considered for long-term investment.

Q10. Is Suven Life Sciences undervalued or overvalued?
Ans: Based on valuation ratios like P/E, P/B, and EV/EBITDA, one can analyse whether the Suven Life Sciences appears undervalued or overvalued at current levels. You can check detailed valuation metrics and peer comparisons on Finology Ticker.

Q11. How to check Suven Life Sciences’s financials?
Ans: You can review Suven Life Sciences’s financial statements - including balance sheet, income statement, and quarterly results - on Finology Ticker.

Last Updated on:
Brief about Suven Life Sciences
X